SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous

August 10, 2023

Completion of Afami-cel's BLA Submission Delayed; FDA Agrees to Cohort 2 of the SPEARHEAD-1 Trial Acting as Confirmatory Evidence for Full Approval; ADP-A2M4CD8's SURPASS-3 Trial Initiated; Adaptimmune's Q2 2023 Earnings Call Summary

Here is a brief preview of this blast: On Wednesday, August 9, Adaptimmune held its Q2 2023 earnings call (press release) disclosing that the completion of afami-cel’s (MAGE-A4 SPEAR-T) BLA submission to the FDA has been postponed to Q4 2023 while reporting the initiation of ADP-A2M4CD8’s (next-generation MAGE-A4 SPEAR-T) Ph2 SURPASS-3 trial. Additionally, management highlighted anticipated milestones for assets included in the combined pipeline resulting from the merger with TCR2 Tx. Below, Celltelligence provides insights on the consequences of the delay in afami-cel’s BLA submission while discussing Adaptimmune’s potential pipeline prioritization strategy in ovarian cancer.